ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) — SC24 — NVIDIA today announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA ® BioNeMo™ Framework to advance drug discovery and accelerate molecule design.
Researchers require specialized biomolecular models and datasets that allow them to gather insights at scale to design therapeutics faster. The open-source BioNeMo Framework offers a collection of accelerated computing tools designed to exponentially scale AI models for biomolecular research, bringing a new level of supercomputing to biopharma.
The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry, said Kimberly Powell, vice president of healthcare at NVIDIA. To help unravel the complexities of biological systems, we’ve introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments.
Pioneering biotech companies, techbio researchers and AI platform companies and organizations are already contributing or will contribute to the open-source framework, including A Alpha Bio; Argonne National Laboratory; Dyno Therapeutics; Genentech, a member of the Roche Group; Ginkgo Bioworks; Relation; VantAI and Weights & Biases. Key research leaders known for advancing computational science also use the BioNeMo Framework to drive innovation.
Argonne has contributed billion-parameter biological models that require specialized software to train across high-performance computing environments, said Arvind (NS:) Ramanathan, computational science group leader at Argonne National Laboratory. With BioNeMo, Argonne and the broader biotech community gain an enterprise-level, open-source solution that enables researchers to easily scale the training of large biological foundation models ” in labs that otherwise wouldn’t have the computational expertise to do so.
Introducing the Next-Generation BioNeMo Platform
The end-to-end NVIDIA BioNeMo platform is designed to accelerate AI model creation, customization and deployment for drug discovery and molecular design. Seamlessly integrated with accelerated computing infrastructure, it reduces costs, increases scale and speeds up drug discovery workflows to provide fast, reliable insights from biomolecular data.
In addition to the BioNeMo…
Click Here to Read the Full Original Article at All News…
